The company is presenting multiple clinical abstracts at a major medical conference, demonstrating progress in its CAR T-cell pipeline. Key positive developments include expanded clinical data for FT819 showing feasibility of outpatient administration without conditioning chemotherapy, biomarker discoveries for improved patient outcomes, and advancement of FT839 into Phase 1/2 trials. These milestones indicate clinical progress and potential for broader patient access to transformative therapies.
Also mentions FATE
Articles that tag FATE but are mainly about other companies.
FT819 allogeneic CAR-T therapy has initiated Phase II RECLAIM-LN trial with FDA RMAT designation, representing a potentially registrational study for lupus nephritis treatment.
Received FDA RMAT designation for FT819 cell therapy in April 2025 and advancing toward Phase II trial commencement, indicating regulatory recognition and accelerated development pathway.
FT819 CAR T-cell therapy accepted into FDA's CDRP Program with RMAT designation; Phase 2 registrational trial planned for lupus nephritis with strong cash runway into 2028.
Achieved landmark clinical milestone with outpatient CAR T-cell therapy for autoimmune diseases, expanding patient access. Strong balance sheet with $205.1M cash and runway through 2027, plus early clinical activity in additional programs.
Achieved significant clinical milestone with off-the-shelf CAR T-cell therapy enabling same-day hospital discharge, expanding patient access and improving health system economics; maintains strong cash position through 2027.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
